IDEAYA Biosciences Reports Strong Clinical Data for Darovasertib in Uveal Melanoma and IDE849 in SCLC at JPM Conference

summarizeSummary

IDEAYA Biosciences presented robust clinical data for its lead programs, Darovasertib and IDE849, at the JPM Healthcare Conference, highlighting significant survival benefits in uveal melanoma and compelling efficacy in small cell lung cancer, alongside a strong financial outlook.

check_boxKey Events

• Darovasertib Shows Significant Survival Benefit in Metastatic Uveal Melanoma

  The combination of Darovasertib and Crizotinib demonstrated a median Overall Survival (OS) of 21.1 months and a median Progression-Free Survival (PFS) of 7.0 months in metastatic uveal melanoma, significantly exceeding historical benchmarks of 10-12 months OS and 2.8 months PFS.

• Pivotal Darovasertib Trial Enrollment Completed

  Full enrollment was completed in December 2025 for the pivotal Phase 2/3 trial (OptimUM-02) in HLA*A2-Negative metastatic uveal melanoma, with randomized PFS results expected to enable a potential U.S. accelerated approval filing.

• IDE849 Demonstrates Strong Efficacy in Small Cell Lung Cancer

  The DLL3 ADC, IDE849, showed a confirmed Objective Response Rate (ORR) of 60.0% and a 6-month PFS rate of 59.0% in the second-line setting of small cell lung cancer (SCLC) in its Phase 1 study, indicating encouraging efficacy and durability.

• Robust Pipeline Progress and Financial Runway

  IDEAYA highlighted a deep pipeline with 9 clinical-stage programs and a strong financial position with approximately $1.1 billion in cash and equivalents, providing a runway into 2030.

auto_awesomeAnalysis

IDEAYA Biosciences presented highly encouraging clinical data for its lead programs at the JPM Healthcare Conference, significantly de-risking its pipeline and enhancing its market position. The reported median overall survival of 21.1 months for Darovasertib in metastatic uveal melanoma substantially exceeds historical benchmarks, indicating a potential breakthrough for this aggressive cancer. The completion of enrollment for the pivotal Phase 2/3 trial further accelerates its path to potential accelerated approval. Additionally, the compelling efficacy and durability data for IDE849 in small cell lung cancer highlight its promise in another difficult-to-treat indication. These positive clinical updates, coupled with a robust cash runway into 2030, provide strong validation for the company's precision medicine oncology strategy and could drive significant investor interest.